Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30851289 | 1.00 | HTR2C (0.57) | HTR2CMEN1POLBKMT2AMAPK1 | |
| SCHEMBL8253641 | 0.90 | HTR2C (0.50) | HTR2CMAP3K12 | |
| Hydrochloric Acid SCHEMBL31500114 | 0.89 | HTR2C (0.51) | HTR2CMAP3K12 | |
| SCHEMBL16452781 | 0.88 | KMT2A (0.42) | HTR2CKMT2A | |
| SCHEMBL29852305 | 0.88 | KMT2A (0.42) | HTR2CKMT2A | |
| Hydrochloric Acid SCHEMBL23211937 | 0.86 | HTR2C (0.47) | HTR2CMEN1POLBKMT2AMAPK1 | |
| SCHEMBL28131310 | 0.84 | ALOX5AP (0.43) | HTR2CKMT2A | |
| SCHEMBL16452775 | 0.84 | PPARD (0.40) | HTR2CKMT2A | |
| SCHEMBL17729510 | 0.83 | CHRNB2 (0.49) | HTR2CKMT2A | |
| SCHEMBL25647216 | 0.83 | PPARD (0.42) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-117642393-A | Novel PARP7 inhibitor and application thereof | 上海齐鲁制药研究中心有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
| US-11352357-B2 | Cycloalkylurea derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220081441-A1 | CYCLOALKYLUREA DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-03-17 | — | — | US | disclosed |
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
| WO-2006106423-A2 | AMINO SULFONYL DERIVATIVES AS INHIBITORS OF HUMAN 11-.BETA.-HYDROSYSTEROID DEHYDROGENASE | PFIZER INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | HSD11B1, HSD11B2, HSD17B11 | HTR2C 499/4885MEN1 2438/4885POLB 4695/4885 |
| US-11352357-B2 | Cycloalkylurea derivative | HCRTR2, HCRTR1, CRHR2 | HTR2C 50/4885MEN1 3411/4885POLB 4382/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | HTR2C 3649/4885MEN1 1218/4885POLB 1788/4885 |
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | HTR2C 3458/4885MEN1 2207/4885POLB 197/4885 |
| US-20220081441-A1 | CYCLOALKYLUREA DERIVATIVE | HCRTR2, HCRTR1, CRHR2 | HTR2C 50/4885MEN1 3411/4885POLB 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.